Key Summary Points {#FPar1}
==================

**Why carry out this study?**Flash glucose monitoring (FGM), a less-invasive glucose monitoring method,has launched in Japan.This study aimed to evaluate patient satisfaction, by using the established questionnaires, and the clinical efficacy of FGM in the patients with type 1 diabetes (T1D).**What was learned from the study?**The scores of the questionnaires related to quality of life (QOL) in T1D patients were significantly improved 12 weeks after using FGM.The values of glycated hemoglobin (HbA1c) and the percentages of time within the target glucose range (3.9--7.8 mmol/L) also improved at 12 weeks after using FGM.Our study suggests that FGM contributed to improving patient satisfaction and the adjustment of blood glucose levels in T1D patients.

Introduction {#Sec1}
============

Patients with diabetes usually experience incessant stress related to dietary restrictions, medical expenses, complications, among others, which often leads to a negative impact on their quality of life (QOL). Studies have shown that patients with diabetes are more susceptible to depression than persons without diabetes \[[@CR1]--[@CR4]\]. In particular, patients with type 1 diabetes (T1D) experience considerable psychological burden due to unexpected fluctuations in blood glucose levels, multiple daily insulin injections, and the need for frequent self-monitoring of blood glucose (SMBG) \[[@CR5]\]. An additional challenge is that patients with T1D often encounter difficulty in achieving optimal glycemic control due to the lack of endogenous insulin secretion and imprecise insulin dosing. Previous studies have shown that only 20% of these patients achieve a glycated hemoglobin (HbA1c) level of \< 52 mmol/mol (\< 7.0%) \[[@CR6], [@CR7]\]. Although frequent SMBG usually results in improved glycemic control \[[@CR8], [@CR9]\], in some patients the frequency of SMBG is low due to their fear of self-testing or their low pain threshold. These factors may affect patients' decisions and behavior regarding the monitoring of their glucose levels \[[@CR10]\]. Hygiene and social obstacles in their schools or workplaces may also deter patients from SMBG.

Following the introduction of continuous glucose monitoring (CGM) systems in clinical practice, it became possible to visualize glucose trends by placing a sensor under the skin. This device is beneficial in terms of identifying hypoglycemia, especially during sleep and between meals, but finger-prick blood sampling is still necessary for calibration purposes. Flash glucose monitoring (FGM) was launched in Japan in September 2017. FGM is a less-invasive glucose monitoring method than SMBG because patients do not need to prick their fingers. The patients can access real-time glucose levels by holding the reader over the sensor placed under their skin, without the need for calibration. Bolinder et al. reported that glycemic control in patients with T1D improved following initiation of FGM \[[@CR11]\].

This less-invasive FGM device can be very useful, especially for patients with T1D who require frequent measurements of glucose levels. Therefore, we hypothesized that FGM could improve the QOL of T1D patients. Since few previous studies have evaluated patient satisfaction as the primary outcome, we performed a prospective study to evaluate patient satisfaction and changes in glycemic control following the introduction of FGM in Japanese patients with T1D.

Methods {#Sec2}
=======

Study Design and Ethics {#Sec3}
-----------------------

This was a prospective, single-center, single-arm study conducted at the National Center for Global Health and Medicine between January 2017 and January 2018. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the ethical committee of the National Center for Global Health and Medicine (ID: NCGM-G-002141--00). Written informed consent was obtained from all the participants.

Participants and Study Assessment {#Sec4}
---------------------------------

Outpatients with T1D and aged 18--75 years were recruited to the study. All patients had to be able to clearly understand the consent form and be capable of providing written consent. Patients with skin disorders were excluded. For FGM, the Free style Libre® (Abbott Medical Japan, LLC, Tokyo, Japan) device was used. The FGM sensors remained attached to the study participants throughout the study period. Patient satisfaction with FGM was assessed using questionnaires before the initiation of FGM (baseline) and at 4 and 12 weeks after initiation of FGM. Also, clinical parameters related to glucose metabolism, such as HbA1c, were obtained from blood analyses, and fluctuations in glucose levels were evaluated using the FGM data. The target range for the blood glucose level was 3.9 to 7.8 mmol/L, and the whole measurement period was divided into three target ranges: \< 3.9, 3.9--7.8, and \> 7.8 mmol/L. The correlation between glucose values obtained using the FGM device and those obtained with SMBG was also investigated for 5 days. Throughout the study period, all patients continued on their insulin therapy, and the dosage of insulin was adjusted to target glucose levels between 5.6 and 7.8 mmol/L before each meal.

Assessment of Patient Satisfaction with FGM Using Questionnaires {#Sec5}
----------------------------------------------------------------

Patient satisfaction with FGM was assessed using the Japanese language versions of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire \[[@CR12]--[@CR14]\]. The DTSQ is composed of eight questions, six of which assess treatment satisfaction. Each question is scored by a patient on a 7-point scale (range 0--6). The six questions on treatment satisfaction ask about "satisfaction with current treatment," "flexibility," "convenience," "understanding of diabetes," "recommend treatment to others," and "willingness to continue," respectively. Treatment satisfaction is evaluated as the summary of scores of the six questions (best total score 36) \[[@CR12], [@CR13]\]. The DTR-QOL questionnaire assesses the influence of diabetes treatment on the patient's QOL. This questionnaire has 29 items, which are divided into four groups: "burden on social activities and daily activities" (13 items), "anxiety and dissatisfaction with treatment" (8 items), "hypoglycemia" (4 items), and "satisfaction with treatment" (4 items) \[[@CR14]\]. In both questionnaires, higher scores indicate higher satisfaction with the treatment.

Statistical Analysis {#Sec6}
--------------------

Data are presented as the mean value ± standard deviation (SD) or the median value and interquartile range (IQR). Scores from the DTSQ and DTR-QOL questionnaire, values for clinical parameters related to glucose metabolism, and fluctuations in glucose at 12 weeks after FGM initiation were compared with those at baseline. The Wilcoxon signed ranked test was used to assess the difference between the two groups. For the analysis, *P* \< 0.05 was considered to be statistically significant. When evaluating the correlation between glucose values obtained using the FGM device and those obtained by SMBG, Spearman's correlation and the mean absolute relative difference (MARD) were calculated. Statistical analysis was conducted with STATA software, version 14.0 (StataCorp, College Station, TX, USA).

Results {#Sec7}
=======

Baseline Characteristics {#Sec8}
------------------------

A total of 21 patients with T1D participated in this study. One patient was excluded due to skin eruptions, and the remaining 20 patients were included in the final analysis. As seen in Electronic Supplementary Material (ESM) Table S1, the mean (± SD) age of the participants was 54.6 ± 14.4 years, and mean diabetes duration was 9.1 ± 11.8 years. Of the 20 patients in the final analysis, 15 received multiple daily insulin injection therapy, and five received insulin pump therapy. Prior to using the FGM device, all participants performed SMBG 4 times a day, once before each meal and before going to bed.

DTSQ and DTR-QOL Scores Improved After the Introduction of FGM {#Sec9}
--------------------------------------------------------------

Following the introduction of FGM, the DTSQ scores were found to have significantly improved from 21.9 ± 8.1 at baseline to 31.5 ± 3.6 at 4 weeks (*P* \< 0.001) and 32.4 ± 3.8 at 12 weeks (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}a). The DTR-QOL scores in all four groups of question items had also significantly improved at 4 weeks after the introduction of FGM, with the scores for "burden in social activities," "anxiety and dissatisfaction with treatment," "hypoglycemia," and "satisfaction with treatment" increasing from 52.8 ± 26.3 (before FGM) to 71.0 ± 23.0 (*P* = 0.009), from 47.2 ± 24.4 to 57.3 ± 23.2 (*P* = 0.047), from 34.8 ± 25.2 to 55.5 ± 29.3 (*P* = 0.046), and from 48.3 ± 25.3 to 65.6 ± 22.9 (*P* = 0.006), respectively. At 12 weeks after initiating FGM, the scores related to "burden in social activities" and "treatment satisfaction with treatment" were significantly higher compared to the scores before the introduction of FGM, increasing from 52.8 ± 26.3 to 67.5 ± 24.7 (*P* = 0.024) and from 48.3 ± 25.3 to 69.5 ± 23.7 (*P* = 0.007), respectively (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Patient scores for the Diabetes Treatment Satisfaction Questionnaire (*DTSQ*) (**a**) and Diabetes Therapy-Related Quality of Life (*DTR-QOL*) questionnaire (**b**) before and 4 and 12 weeks after the initiation of Flash glucose monitoring. Higher scores indicate higher satisfaction with the treatment. *FGM* Flash glucose monitoring. \*Significantly different at *P* \< 0.05 compared with the scores before the introduction of FGM

HbA1c Levels and Percentage of Time Spent in Target Glucose Range Improved After the Introduction of FGM {#Sec10}
--------------------------------------------------------------------------------------------------------

The HbA1c levels significantly decreased from 58 ± 5 mmol/mol (7.46 ± 0.66%) at baseline to 56 ± 5 mmol/mol (7.32 ± 0.66%) (*P* = 0.041) and 54 ± 4 mmol/mol (7.16 ± 0.58%) (*P* = 0.002) at 4 and 12 weeks after the introduction of FGM, respectively (Table [1](#Tab1){ref-type="table"}). Moreover, at 12 weeks, the standard deviation of glucose levels obtained from the FGM data improved significantly from 3.6 ± 0.9 to 3.3 ± 1.0 mmol/L (*P* = 0.035), as did the percentage of time spent within the target glucose range (3.9--7.8 mmol/L) at 12 weeks after initiating FGM. The percentage of time in glucose levels below and above the target range were not significantly changed after the introduction of FGM.Table 1Glycated hemoglobin levels and results of flash glucose monitoring (FGM) analysis before and 4 and 12 weeks after the introduction of FGMParametersBefore FGM4 weeks after initiating FGM12 weeks after initiating FGMHbA1c (mmol/mol)58 ± 556 ± 5\*54 ± 4\*Average glucose (mmol/L)9.3 ± 1.99.0 ± 1.58.7 ± 1.2SD of glucose (mmol/L)3.6 ± 0.93.4 ± 0.93.3 ± 1.0\*Percentage of time spent within the range of glucose levels \< 3.9 mmol/L4 (1--5.5)4 (1--6)2 (0--10) 3.9--7.8 mmol/L36 (25--44.5)41 (33--52.5)44 (39--50)\* \> 7.8 mmol/L60 (47--69.5)55 (44.5--65.5)54 (42.5--61.5)Data are expressed as the mean ± standard deviation (SD) for glycated hemoglobin (HbA1c), average glucose, and SD of glucose, and as median with the interquartile range in parenthesis for the percentage of time spent within the range of glucose levels\*Significant difference at *P* \< 0.05 compared with the values before the introduction of FGM

Correlation Between Glucose Values Obtained Using FGM and Those Obtained by SMBG {#Sec11}
--------------------------------------------------------------------------------

Glucose values obtained using the FGM device were significantly correlated with those obtained by SMBG (*R*^2^ = 0.881, *P* \< 0.0001). The MARD between glucose values obtained by FGM and SMBG was 12.2% throughout the study period (ESM Fig. S1).

Correlation Between the Frequency of Glucose Scanning with the FGM Device and Changes in DTSQ Scores and HbA1c Levels {#Sec12}
---------------------------------------------------------------------------------------------------------------------

The frequency of glucose scanning with FGM was not significantly correlated with changes in either DTSQ scores (ESM Fig. S2a) or HbA1c levels (ESM Fig. S2b) during the study period (*R*^2^ = 0.055 and *R*^2^ \< 0.001, respectively).

Discussion {#Sec13}
==========

The results of our study demonstrated that FGM contributed to improved patient satisfaction, as evaluated by two questionnaires related to QOL and glycemic control during the 12-week study period in patients with T1D. The accuracy of FGM was also reconfirmed in our study.

The DTSQ scores significantly improved from 21.9 ± 8.1 at baseline to 32.4 ± 3.8 at 12 weeks after the introduction of FGM. The changes in the DTSQ scores in our study are relatively larger than those reported in other studies. For example, Akiko et al. reported that the scores improved from 19.4 to 23.9 when the carbohydrate counting system was introduced in patients with T1D \[[@CR15]\]. The DTR-QOL scores in our study were especially related to "burden on social and daily activities" and "satisfaction with treatment," and the scores for these two groups were also significantly higher following the initiation of FGM. These high scores may be related to the ease and low invasiveness of FGM. The DTR-QOL scores related to "anxieties and dissatisfactions" and "hypoglycemia" also improved 4 weeks after the introduction of FGM; these scores were low in one-third of the participants. While the patients could easily access real-time glucose levels with FGM any time they wanted, some of them felt more anxious about hypoglycemia and hyperglycemia when they saw several values of glucose levels. These results suggest that the personality and character of a patient needs be taken into consideration during decision-making on whether to initiate FGM.

Interestingly, the HbA1c levels of the patients in our study significantly improved during the study period, in contrast to results reported by Bolinder et al. which showed that FGM reduced the time spent in and incidence of hypoglycemia, but did not decrease the HbA1c levels \[[@CR11]\]. The main reason for this difference may be that the mean initial HbA1c levels of the patients in our study were higher than those of patients included in the earlier study (58 vs. 48 mmol/mol \[7.46 vs. 6.70%\]). This possibility is supported by a study by Evans et al. who found that changes in HbA1c levels are affected by the initial values \[[@CR16]\]. Conversely, a number of other recent studies have shown that the introduction of FGM contributed to the reduction of HbA1c levels, similar to what we demonstrated in our study \[[@CR16], [@CR17]\]. Furthermore, in our study, the SD of glucose levels and the percentage of time spent in target glucose range had improved without any increase in the percentage of time in hypoglycemia. These results were possible because the patients could perform certain interventions, such as modifying glucose intake or an additional bolus insulin injection, by monitoring their glucose trend with the FGM device, thereby avoiding both hypoglycemia and hyperglycemia. Accordingly, FGM can be a good option for managing T1D because achieving better HbA1c levels, avoiding hypoglycemia, and regulating glucose fluctuations are regarded as important therapeutic goals \[[@CR18]\].

Our study had a number of limitations. First, it was an exploratory study with a single-arm, a relatively low number of participants, and a short observation period. Large changes in the QOL scores in a few patients might therefore affect the results in a study with small number of participants. Second, since the participants were older than 18 years and not pregnant, it is unclear whether FGM can be a satisfactory option for patients in the younger age group and pregnant women, who might behave differently from the participants of our study. Third, although the target blood glucose level was 3.9--7.8 mmol/L before each meal, we did not use any strict algorithm for insulin adjustment. Therefore, randomized studies with a higher number of patients, longer duration, and strict algorithms for insulin adjustment should be considered in the future.

Conclusions {#Sec14}
===========

The results of our study suggest that FGM contributes to improving patient satisfaction and enables a better adjustment of glucose levels in patients with T1D.
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